The antisense oligonucleotide Nusinersen has been recently licensed to treat spinal muscular atrophy (SMA). Since SMA type 3 is characterized by variable phenotype and milder progression, biomarkers of early treatment response are urgently needed.
| INTRODUC TI ON
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease caused by mutations in the Survival Motor Neuron 1 (SMN1) gene. The most severe form of this disease, SMA type 1, becomes evident in the firsts months of life and is currently the most common genetic cause of death in infancy. 1 On the other hand, individuals affected by SMA type 3 usually display a milder phenotype and a more indolent disease progression; despite this, most patients lose their ability to walk independently in adulthood. 2 The main determinant of these different outcome relates to the variable copy number of the gene SMN2 3 : Most of the SMN protein that derives from this paralogous gene is rapidly degraded, but up to 10% of the total protein product is functional and may in part compensate the complete lack of SMN1. However, other factors are likely to play a role in determining the clinical phenotype. 4 Nusinersen, the first marketed disease-modifying drug for SMA, 5 is an antisense oligonucleotide that binds to the SMN2 pre-mRNA downstream of exon 7, leading to the translation of a fully functional SMN protein. Nusinersen is administered intrathecally by lumbar puncture and has been recently licensed in Europe to treat SMA in each country with specific indications for the different types of SMA. 6 Results of clinical trials have shown a dramatic clinical and laboratory response after Nusinersen administration in SMA type 1 patients, 7 while recent studies on late-onset SMA type 3 provided less striking, albeit encouraging results. 8 Indeed, SMA type 3 patients display a highly variable phenotypic spectrum of disease and, due to the relatively milder progression typical of this subset of patients, clinical differences may theoretically become evident only after prolonged treatment. Considering the scant data available on Nusinersen efficacy in this population and the high cost of this intrathecally administered drug, robust biomarkers of early treatment response are required to identify patients who could benefit from treatment.
Phosphorylated neurofilament heavy chain (pNfH) and neurofilament light chain (NfL) have been reproducibly associated with axonal degeneration, 9 and levels of these biomarkers tend to increase in both cerebrospinal fluid (CSF) and plasma/serum of patients affected by motor neuron diseases (MNDs). As a result, neurofilaments have been increasingly recognized as a useful biomarker for the diagnosis of amyotrophic lateral sclerosis, and their concentration in the CSF is affected by disease duration, rate of progression and involvement of first-and second-motor neurons. 10 A recent study suggested that plasma pNfH could be exploited as a biomarker of treatment response to Nusinersen in SMA type 1 patients 7 : increased pNfH levels at baseline with respect to 34 controls showed a rapid and substantial decline after only two months from treatment start, reaching a 90.1% relative change at 10 months. In the present study, we aimed to assess the levels and changes over time of pNfH and NfL in the CSF of type 3 SMA patients treated with intrathecal Nusinersen, to explore their use as a potential biomarkers of treatment response. The study was conducted in accordance with the Declaration of Helsinki and followed ICH GCP guidelines. All subjects and the parents of minors provided written informed consent for the collection, storage and analysis of biological materials according to the disposition of the local ethics committees.
| MATERIAL S AND ME THODS

| Clinical evaluation
| CSF analysis
Cerebrospinal fluid samples were collected right before the intrathecal administration of Nusinersen. Analyses were performed on samples obtained on the first (pre-treatment) and on the last administration (6 months). CSF analyses were also performed on selected samples from subjects who underwent lumbar puncture during a diagnostic procedure for unconfirmed clinical suspicions and who were ultimately diagnosed with psychosomatic diseases.
Patients with different neurological conditions (excluding neurodegenerative/motor neuron disorders) with an age range comparable to SMA patients were also included. CSF pNfH and NfL levels were measured performed with commercially available enzyme-linked immunosorbent assay (ELISA) kits (pNfH: Euroimmun, Lubeck, Germany-NfL: UmanDiagnostics AB, Umea, Sweden) according to the manufactures' instructions. 
| Statistical analysis
| RE SULTS
| Clinical assessment
A total of 12 patients diagnosed with SMA type 3 were enrolled in the study. The age of first treatment ranged from a minimum of nine to a maximum of 74 years, with nine patients (75%) >18 years old.
The minimum disease duration at the start of treatment is 7.5 years, while the maximum duration is 32 years. Baseline characteristics are summarized in Table 1 . Two patients used wheelchairs since the age of 18 and 29 years, and another two had mild respiratory involvement due to restrictive pulmonary disease and obstructive sleep-apnoea syndrome respectively. Ten patients were ambulant, but one of them needed support and was able to walk only for few steps, while another one underwent minor orthopaedic surgery at the beginning of the observation period, thus only eight patients were able to perform the 6WMT both at baseline and at the end of the follow-up. A single patient with SMA type 1, who started therapy at the age of 3 months, was also included as reference. All Nusinersen administrations were well-tolerated, and the only adverse event reported was headache after lumbar puncture in 6 (50%) subjects after the first drug infusion.
Motor functions were not significantly modified by Nusinersen in SMA type 3 patients during the 6-month follow-up, with a non-significant trend towards improved performances in the 6-minutes walking test (+4.0 ± 17.7 metres, P = .54) and in the HFMSE score (+1.0 ± 3.8 points, P = .38) compared to baseline ( Figure 1A and 1 , respectively).
| Neurofilaments in the CSF
pNfH and NfL levels dosed at baseline in the CFS of SMA type 3 patients were comparable to those observed in controls (n = 9, age: 29.0 [22.0-54.5] year-old) and were far below the average values described in patients affected by either SMA type 1 (6.874 ng/mL and >10 000 pg/ mL, respectively) or amyotrophic lateral sclerosis (5.270 ng/mL and 2961 pg/mL 11 ) (Figure 2A and 2) . The baseline concentration of neurofilaments in our study was below the lower limit of quantification in a significant proportion of patients (4/12 and 2/12 for pNfH and NfL respectively). In these cases, lower limit of quantification was approximated to half of the concentration of the lowest calibrator (50 pg/mL and 0.0625 ng/mL for NfL and NfH, respectively).
No significant correlation was observed between pNfH and either age at treatment or duration of the disease ( Figure 2B and 2) . On the other hand, a positive correlation was found between NfL and age at treatment (r = 0.59, P = .046) along with a marginally significant correlation between NfL and duration of the disease (r = 0.55, P = .066) ( Figure 2E and 2) .
Interestingly, the comparison between the values of both neurofilament types before and after 6 months from treatment start showed a slight but significant decrease (pNfH: median of differences −0.0236 ng/mL, P = .016-NfL: mean of differences −70.0 ± 97.7 pg/mL, P = .031) ( Figure 3A and 3) . However, no significant correlation was observed between the pre-post-difference in HFMSE scores and the change of either pNfH or NfL over time ( Figure 3B and 3) .
Baseline values of both pNfH and NfL in the patient with SMA type 1 were much higher than those observed in healthy controls (6.874 ng/ mL and >10 000 pg/mL, respectively), in accordance with existing data TA B L E 1 Baseline clinic characteristics of SMA type 3 patients 7, 12 Levels of both neurofilament types showed a progressive and rapid reduction, and at 6 months from treatment start they were comparable to those of healthy individuals (data not shown).
| D ISCUSS I ON
In this explorative study on a small cohort of SMA type 3 patients, we report our preliminary findings on the effects of Nusinersen administration on motor function over the short-term and describe changes over time in the CSF concentration of both pNfH and NfL, which were assessed as potential biomarkers of treatment response.
At 6 months from treatment start, we observed a slight improvement in motor functions of treated patients, which, however, did not reach nominal significance compared to pre-treatment values. A recent post hoc analysis of data from the CS2/CS12 study, which included a subset of ambulant patients with SMA type 2 and 3 treated with Nusinersen, showed an improvement in motor performance (measured by the 6MWT) at 35 months from treatment start. 13 The apparent inconsistence with our results is probably due to the significantly different follow-up extension, to baseline patient characteristics and disease duration. In our study, we selectively recruited is less likely to significantly affect neurofilament concentration. As previously described for healthy individuals, 15 NfL concentration was positively correlated with age and duration of the disease in SMA type 3 patients, while pNfH levels were less influenced by patient age and disease duration.
Near-normal baseline values notwithstanding, the CSF concentration of both pNfH and NfL was significantly reduced at 6 months compared with pre-treatment values. This finding might suggest an early biochemical effect of treatment, possibly reflecting decreased axonal degeneration, which may be captured well before any change in motor performance becomes clinically evident.
Similarly to our study, Wurster and colleagues 16 have elegantly described the changes of CSF parameters over time in a cohort of SMA type 2 and 3 patients treated with Nusinersen. In their report, however, no significant difference in neurofilament concentrations was found between pre-and post-treatment samples. Our study design may have granted us more power to detect significant changes owing to its longer follow-up (6 months compared with 2 months after treatment start) and to the cohort restricted to SMA type 3 patients.
In addition, patients enrolled in our study had an overall shorter disease duration, which may have further affected results. Notably, some of the variability in results could be potentially related to difference in sensitivity among ELISA kits employed, especially for pNfH levels.
Despite these encouraging results, we did not observe any significant correlation between neurofilament concentration over time and the change in motor functions at six months as assessed by the HFMSE score. We speculate that the lack of a significant clinical effect during this relatively short follow-up may in part explain this inconsistency.
Indeed, important limitations of our study include the small number of patients and the relatively short duration of follow-up.
In addition, analytical limitations need to be discussed: the baseline concentration of neurofilaments in our study was below the lower limit of quantification in a significant proportion of patients (4/12 and 2/12 for pNfH and NfL, respectively), thus hindering data interpretation. However, the remarkable consistency of measurable data and the significant differences observed despite such limitation, infers against a casual effect. These concerns may be addressed in future by the use of more sensitive methods designed to detect lower analyte concentrations, such as the single-molecule array immunoassay that has been recently developed for NfL detection. 17 Overall, our studies suggest that both pNfH and NfL are reduced by Nusinersen administration in a significant proportion of SMA type 3 patients as early as six months after the first treatment, and mandate further investigation on the accuracy of neurofilaments as markers of treatment response.
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